Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment.
about
Adenoviral vectors for prodrug activation-based gene therapy for cancerImportant role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistanceEngineering cytochrome P450 biocatalysts for biotechnology, medicine and bioremediationDominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinibThe anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, Hepatic Cytochrome P450 Reductase Null (HRN™) mice and pure enzymes.Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantroneThrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis.Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model.Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinibAnti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2Tumor pO₂ as a surrogate marker to identify therapeutic window during metronomic chemotherapy of 9L gliomas.
P2860
Q26860729-7533ACEC-BCC6-4B3E-BD38-88BB64D8FEF9Q28538733-9AC7C8FF-1DDF-48B8-89DF-7A782C5946BDQ28749176-F505B40C-4565-4427-A348-3A30DD4535C6Q33400232-E0AFF6E3-2781-4C0F-A469-773EC6F89666Q35016427-E3325831-212D-41FD-97F0-3E2F5EE0BF16Q36573248-D3FDE12D-5229-4F59-BDFB-9255B31E4388Q36586178-587F392E-B42D-46DA-8A2F-53C377CD6392Q37276853-1F766E30-C4E4-4E77-851D-3A743CFCD045Q37346912-5F2566CA-F404-4F0B-831C-91E218289E05Q38568650-AC279905-78BC-46FD-B7E5-98ADB48684C5Q42037461-F0C2B08B-0077-4817-8EE4-6F33518D560FQ42838672-68E2EC44-2410-41D2-8C6B-ED3BA337A792
P2860
Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Collaboration between hepatic ...... py model for cancer treatment.
@en
type
label
Collaboration between hepatic ...... py model for cancer treatment.
@en
prefLabel
Collaboration between hepatic ...... py model for cancer treatment.
@en
P2860
P1476
Collaboration between hepatic ...... py model for cancer treatment.
@en
P2093
P2860
P304
P356
10.1158/1535-7163.MCT-07-0297
P577
2007-11-07T00:00:00Z